Vegfa - vascular endothelial growth factor A Gene

Also Known as VPF; Vegf; VEGF-A; VEGF111; VEGF164

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 83785

Summary

This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]

Vegfa Products (13)

mRNA Protein Name
NM_001110333.2 NP_001103803.1 vascular endothelial growth factor A isoform 2
NM_001110334.2 NP_001103804.1 vascular endothelial growth factor A isoform 3
NM_001110335.1 NP_001103805.1 vascular endothelial growth factor A isoform 4
NM_001110336.1 NP_001103806.1 vascular endothelial growth factor A isoform 5
NM_001287107.1 NP_001274036.1 vascular endothelial growth factor A isoform 6 precursor
NM_001287108.1 NP_001274037.1 vascular endothelial growth factor A isoform Vegf-A precursor
NM_001287110.1 NP_001274039.1 vascular endothelial growth factor A isoform 8 precursor
NM_001287111.1 NP_001274040.1 vascular endothelial growth factor A isoform 9
NM_001287112.1 NP_001274041.1 vascular endothelial growth factor A isoform 10 precursor
NM_001287113.1 NP_001274042.1 vascular endothelial growth factor A isoform 11
NM_001287114.1 NP_001274043.1 vascular endothelial growth factor A isoform 12
NM_001317043.1 NP_001303972.1 vascular endothelial growth factor A isoform Vegf-Ax precursor
NM_031836.3 NP_114024.2 vascular endothelial growth factor A isoform 1

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables chemoattractant activity IMP
IMP: Inferred from mutant phenotype
23226762 RGD
enables growth factor activity IDA
IDA: Inferred from direct assay
12181492 RGD
enables growth factor binding IPI
IPI: Inferred from physical interaction
17881084 RGD
enables identical protein binding IPI
IPI: Inferred from physical interaction
2320579 RGD
enables vascular endothelial growth factor receptor 2 binding IMP
IMP: Inferred from mutant phenotype
18614764 RGD
Biological Process GO Annotation Evidence References Source
involved in T-helper 1 type immune response IDA
IDA: Inferred from direct assay
15034080 RGD
involved in angiogenesis IMP
IMP: Inferred from mutant phenotype
16230500 RGD
involved in angiogenesis involved in coronary vascular morphogenesis IMP
IMP: Inferred from mutant phenotype
11397779 RGD
involved in blood vessel remodeling IMP
IMP: Inferred from mutant phenotype
16203926 RGD
involved in cell chemotaxis IMP
IMP: Inferred from mutant phenotype
23226762 RGD
involved in cellular response to dexamethasone stimulus IEP
IEP: Inferred from expression pattern
10215998 RGD
involved in cellular response to estrogen stimulus IEP
IEP: Inferred from expression pattern
17272396 RGD
involved in cellular response to fibroblast growth factor stimulus IEP
IEP: Inferred from expression pattern
18617696 RGD
involved in cellular response to mechanical stimulus IEP
IEP: Inferred from expression pattern
19012730 RGD
involved in cellular response to wortmannin IEP
IEP: Inferred from expression pattern
17272396 RGD
involved in cellular response to xenobiotic stimulus IEP
IEP: Inferred from expression pattern
22326847 RGD
involved in female pregnancy IEP
IEP: Inferred from expression pattern
16959835 RGD
involved in lung alveolus development IMP
IMP: Inferred from mutant phenotype
16230500 RGD
involved in mRNA stabilization IDA
IDA: Inferred from direct assay
12881220 RGD
involved in negative regulation of bone resorption IMP
IMP: Inferred from mutant phenotype
15312247 RGD
involved in negative regulation of programmed cell death IMP
IMP: Inferred from mutant phenotype
18614764 RGD
involved in nervous system development IDA
IDA: Inferred from direct assay
12181492 RGD
involved in neuron apoptotic process IMP
IMP: Inferred from mutant phenotype
17591953 RGD
involved in positive regulation of angiogenesis IDA
IDA: Inferred from direct assay
23562340 RGD
involved in positive regulation of cell population proliferation IMP
IMP: Inferred from mutant phenotype
18614764 RGD
involved in positive regulation of signal transduction IDA
IDA: Inferred from direct assay
12483534 RGD
involved in positive regulation of smooth muscle cell proliferation IMP
IMP: Inferred from mutant phenotype
14693680 RGD
involved in positive regulation of transcription by RNA polymerase II IDA
IDA: Inferred from direct assay
12881220 RGD
involved in positive regulation of vascular permeability IMP
IMP: Inferred from mutant phenotype
16793871 RGD
involved in response to dexamethasone IEP
IEP: Inferred from expression pattern
16959835 RGD
involved in response to estradiol IEP
IEP: Inferred from expression pattern
8344219 RGD
involved in response to folic acid IEP
IEP: Inferred from expression pattern
17482424 RGD
involved in response to hypoxia IDA
IDA: Inferred from direct assay
12881220 RGD
involved in response to oxygen levels IEP
IEP: Inferred from expression pattern
15885787 RGD
involved in response to progesterone IEP
IEP: Inferred from expression pattern
8344219 RGD
involved in response to vitamin A IEP
IEP: Inferred from expression pattern
23106861 RGD
involved in tissue remodeling IEP
IEP: Inferred from expression pattern
23887904 RGD
involved in vascular endothelial growth factor receptor signaling pathway IMP
IMP: Inferred from mutant phenotype
18614764 RGD
Cellular Component GO Annotation Evidence References Source
located in basement membrane IDA
IDA: Inferred from direct assay
11940521 RGD
located in extracellular space IDA
IDA: Inferred from direct assay
15034080 RGD
located in vesicle IDA
IDA: Inferred from direct assay
18758911 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

vascular endothelial growth factor A

  • vascular permeability factor

Recombinant Vegfa Proteins

Cat. No. Product Name Accession Purity
HY-P7311 VEGF164 Protein, Rat (CHO) P16612-2 (A27-R190) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P70638 VEGF164 Protein, Rat (P.pastoris) P16612-2 (A27-R190, A36T) ≥ 95%, as determined by reducing SDS-PAGE.
HY-P76122 VEGF164 Protein, Rat (sf9) P16612-2 (A27-R190) ≥ 95%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-P9906 Bevacizumab Inhibitor ≥99.0% Unkown
HY-P9906A Bevacizumab (Anti-VEGFA) Inhibitor 99.07% Unkown
HY-P99116 Faricimab Inhibitor 97.97% Unkown
HY-P9973 Brolucizumab Inhibitor 99.90% Unkown

Clinical Phase

Bioactive Molecules (6)
Cat. No. Product Name Effect
Purity Phase
HY-P10284 S7 98.25% Phase 4
HY-124593 PTC299 Inhibitor 99.71% Phase 3
HY-B1788 Taurocholic acid 99.83% Phase 2
HY-N0545 Taurocholic acid sodium Agonist 99.82% Phase 2
HY-P3369 Gersizangitide 97.16% Phase 2
HY-B1788R Taurocholic acid (Standard) 99.91% Phase 2
Inhibitory Antibodies (12)
Cat. No. Product Name Effect
Purity Phase
HY-P99675 Ivonescimab Inhibitor 99.13% Phase 4
HY-P99830 Conbercept Inhibitor 98.42% Phase 4
HY-P991097 Pumitamig Inhibitor 99.6% Phase 3
HY-P99576 Tarcocimab Inhibitor 98.35% Phase 3
HY-P991033 Tovecimig 97.39% Phase 3
HY-P990082 Suvemcitug Inhibitor 96% Phase 3
HY-P991416 BAT5906 Inhibitor / Phase 3
HY-P991418 MW02 Inhibitor / Phase 3
HY-P99330 Vanucizumab Inhibitor 95.12% Phase 2
HY-P991738 LM-299 95.78% Phase 2
HY-P990689 Zifibancimig Inhibitor 99.00% Phase 2
HY-P991417 LYN00101 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (36)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-10799 EG00229 trifluoroacetate Antagonist 98.03% Unkown
HY-117661 SPHINX31 Inhibitor 99.25% Unkown
HY-B1131 Taurocholic acid sodium salt hydrate 98.51% Unkown
HY-N2187 Deoxyshikonin 99.96% Unkown
HY-144707 AK-778-XXMU 99.96% Unkown
HY-P10831 GNQWFI Antagonist 99.82% Unkown
HY-115746 Dimethyl-bisphenol A Inhibitor 99.78% Unkown
HY-N7043 Isosilybin A 99.63% Unkown
HY-N0545R Taurocholic acid sodium (Standard) Agonist 97.91% Unkown
HY-N10336 Notoginsenoside R4 99.90% Unkown
HY-138647 TGP-377/421 Inhibitor 98.17% Unkown
HY-W653842 Taurocholic acid-d8 sodium Agonist 98.83% Unkown
HY-101931 hVEGF-IN-1 Inhibitor 99.25% Unkown
HY-182700 NRPa-308 Inhibitor 98.96% Unkown
HY-P10971 Nef-M1 98.87% Unkown
HY-124722 OHM1 Inhibitor / Unkown
HY-149886 HIF-2α-IN-9 Inhibitor / Unkown
HY-163760 ZM-32 Inhibitor / Unkown
HY-168560 MMP Inhibitor 4 Inhibitor / Unkown
HY-176805 TGP-377 / Unkown
HY-179350 EG01449 Free acid Inhibitor / Unkown
HY-179350A EG01449 Inhibitor / Unkown
HY-182639 AM9928 Inhibitor / Unkown
HY-18333 EG00229 Inhibitor / Unkown
HY-N0545S2 Taurocholic acid-d4-1 sodium / Unkown
HY-N19872 Mukurozioside IIb / Unkown
HY-N19873 Mukurozioside IIa / Unkown
HY-P10550 VGB4 Antagonist / Unkown
HY-P3990 Coibamide A / Unkown
HY-RS15635 VEGFA Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-128446 CAY10781 Inhibitor 98.04% Unkown
HY-174510 Human VEGFA mRNA / Unkown
HY-B1788S2 Taurocholic acid-d5 / Unkown
HY-RS16537 Vegfa Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS22968 Vegfa Rat Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W653893 Taurocholic acid-d5 sodium Agonist / Unkown
Inhibitory Antibodies (8)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P9920A Ramucirumab (anti-VEGFR) Antagonist 99.9% Unkown
HY-P9951A Ranibizumab (anti-VEGF) Inhibitor 99.60% Unkown
HY-P990148 Anti-Mouse VEGF-A Antibody (2G11-2A05) Inhibitor 97.40% Unkown
HY-P992139 Valancitug Inhibitor 97.61% Unkown
HY-P991625 VX70 / Unkown
HY-P992323 BI-836880 Inhibitor / Unkown
HY-P992511 CS2009 Inhibitor / Unkown
HY-P992518 Pumitamig (Mouse IgG2a) Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Vegfa NCBI NCBI:7422